UK Healthtech Startup Nul Secures $1M To Expand Alcohol Reduction Platform

Alcohol use disorder and harmful drinking affect millions globally, yet treatment options have seen little innovation in recent decades. Nul addresses this gap with medication- and therapy-supported reduction programs designed for individuals seeking to lower alcohol consumption without immediate or complete abstinence.

Founded by Matus Maar, Nul is building a telehealth platform that integrates clinical care, prescription medication, digital treatment pathways, and behavioral support. The program is based on naltrexone, a medication that reduces alcohol cravings by targeting reward pathways.

Read Also - Intuos Raises €720K To Enhance Non-Commercial Aviation Safety And Operations

Delivered via a fully remote subscription service, the platform provides virtual consultations, ongoing clinical support, and structured digital guidance following The Sinclair Method.

Commenting on the mission, Matus Maar, CEO of Nul, said alcohol reduction remains one of the largest healthcare areas that has experienced relatively little modernization.

Telehealth and online pharmacy platforms have transformed categories like weight loss and mental health, yet alcohol has been left behind despite the scale of the problem. Nul is about making evidence-based treatment accessible, discreet and compatible with real life.

Nul launched a UK test phase in summer 2025, onboarding over 120 paying customers and achieving an annualized revenue run rate of more than £300,000 within its first months, fueled primarily by organic demand and word-of-mouth.

The seed funding will enable Nul’s full UK commercial launch, expansion of its clinical and product teams, scaling of customer acquisition, and preparation for future international growth, including entry into the US market.

In addition, Nul plans to launch a crowdfunding campaign on Republic Europe, giving retail investors the opportunity to support the company’s next stage of growth.